Skip to main content
. 2021 Sep 3;4(9):e2122607. doi: 10.1001/jamanetworkopen.2021.22607

Table 2. Primary and Secondary Outcomesa.

Outcome Patient group OR (95% CI) P value
ON101 (n = 122) Absorbent dressing (n = 114)
Complete healing, No. (%)
FAS 74 (60.7) 40 (35.1) 2.84 (1.66-4.84) <.001b
mITT 73 (61.9) 38 (33.9) 3,15 (1.82-5.43) <.001b
Secondary
Change in WSA from baseline to visit 10, mean (SD), % −78.0 (42.6) −78.0 (34.9) NA .89
Incidence of patients with 50% reduction in WSA on visit 10, No. (%) 101 (82.8) 98 (86.0) 0.80 (0.39-1.62) .53b
Incidence of wound infection 6 (4.9) 7 (6.1) NA .78
Ulcer recurrence, No. (%)c 15 (20.3) 7 (17.5) NA .81
Safety
Patients with TEAEs, No. (%) 76 (62.3) 77 (67.5) NA .42
No. of TEAEs 207 235 NA
Related TEAEs
Patients, No. (%) 7 (5.7) 5 (4.4) NA .77
No. of events 11 5 NA NA
Serious TEAEs
Patients, No. (%) 14 (11.5) 9 (7.9) NA .39
No. of events 24 14 NA NA
Related serious TEAEs in events, No. (%) 0 1 (0.9) NA <.48
TEAE leading to death, No. 0 0 NA NA
Subgroup analysis
Wound closure, No./total No. (%)
HbA1c level
<9% 59/90 (65.6) 33/82 (40.2) 2.81 (1.50-5.26) <.001b
≥9% 15/32 (46.9) 7/32 (21.9) 3.14 (1.04-9.50) .04b
Ulcer size, cm2
1-5 55/88 (62.5) 31/77 (40.3) 2.46 (1.31-4.61) .005b
>5 18/33 (54.5) 8/36 (22.2) 4.09 (1.42-11.80) .009b
Ulcer duration, mo
<6 mo 62/86 (72.1) 36/79 (45.6) 3.07 (1.59-5.95) <.001b
≥6 mo 12/36 (33.3) 4/35 (11.4) 3.99 (1.09-14.63) .04b

Abbreviations: FAS, full-analysis set; HbA1c, glycated hemoglobin; mITT, modified intent-to-treat; NA, not applicable; OR, odds ratio; TEAEs, treatment-emergent adverse events; WSA, wound (ulcer) surface area.

a

The absorbent dressing used was Hydrofiber (ConvaTec Ltd).

b

Calculated using a logistic regression model. Treatment was the main exposure variable; the baseline wound size in cm2 and Wagner grade were covariates.

c

Ulcer recurrence was recorded once the ulcer had healed completely and was observed during the follow-up period.